Complement-protected amphotropic retroviruses from murine packaging cells

Human Gene Therapy

Volumn 10, Issue 11, 1999, Pages 1893-1902

  Spitzer, Dirk ^a   Hauser, Hansjörg ^a   Wirth, Dagmar ^a  

^a HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT; DECAY ACCELERATING FACTOR; HYBRID PROTEIN; REGULATOR PROTEIN; VIRUS ENVELOPE PROTEIN; VIRUS VECTOR;

ANIMAL CELL; ARTICLE; CELL STRAIN 3T3; COMPLEMENT SYSTEM; GENE THERAPY; HELPER CELL; IMMUNOBLOTTING; MOLECULAR WEIGHT; MOUSE; MURINE LEUKEMIA VIRUS; NONHUMAN; PROTEIN DOMAIN; PROTEIN EXPRESSION; RETROVIRUS; SERUM; VIRION; VIRUS INACTIVATION; VIRUS PARTICLE;

3T3 CELLS; ANIMALS; ANTIBODIES; ANTIGENS, CD55; BLOTTING, WESTERN; CELL LINE; CELL MEMBRANE; COMPLEMENT SYSTEM PROTEINS; GENE THERAPY; HUMANS; LEUKEMIA VIRUS, MURINE; MACACA MULATTA; MICE; RECOMBINANT FUSION PROTEINS; VIRAL ENVELOPE PROTEINS;

AMPHOTROPIC MURINE LEUKEMIA VIRUS; ANIMALIA; MURINAE; UNIDENTIFIED RETROVIRUS;

EID: 0033587582     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/10430349950017572     Document Type: Article

References (36)

1. COLBÈRE-GARAPIN, F., HORODNICEANU, F., KOURILSKY, P., and GARAPIN, A.-C. (1981). A new dominant hybrid selective marker for higher eukaryotic cells. J. Mol. Biol. 150, 1-14.
2. COOPER, N.R., JENSEN, F., RAYMOND, M.W., and OLDSTONE, M.B.A. (1976). Lysis of RNA tumor viruses by human serum: Direct antibody-independent triggering of the classical complement pathway. J. Exp. Med. 144, 970-984.
3. COSSET, F.L., MORLING, F.J., TAKEUCHI, Y., WEISS, R.A., COLLINS, M.K., and RUSSEL, S.J. (1995a). Retroviral retargeting by envelopes expressing an N-terminal binding domain. J. Virol. 69, 6314-6322.
4. COSSET, F.L., TAKEUCHI, Y., BATTINI, J.L., WEISS, R.A., and COLLINS, M.K. (1995b). High titer packaging cells producing recombinant retroviruses resistant to human serum. J. Virol. 69, 7430-7436.
5. CULVER, K.W., RAM, Z., WALBRIDGE, S., ISHII, H., OLDFIELD, E.H., and BLAESE, R.M. (1992). In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 256, 1550-1552.
6. CULVER, K.W., VAN GILDER, J., LINK, C.J., CARLSTORM, T., YUH, W., KOCH, K., DOORNBAS, S., WETJEN, B., and BLAESE, R.M. (1994). Clinical protocol: Gene therapy for the treatment of malignant brain tumors with in vivo tumor transduction with the herpes simplex thymidine kinase gene/ganciclovir system. Hum. Gene Ther. 5, 343-379.
7. DANOS, O., and MULLIGAN, R.C. (1988). Safe and efficient generation of recombinant retroviruses with amphotropic and ecotropic host ranges. Proc. Natl. Acad. Sci. U.S.A. 85, 6460-6464.
8. DIRKS, W., WIRTH, M., and HAUSER, H. (1993). Dicistronic transcription units for gene expression in mammalian cells. Gene 128, 247-249.
9. FODOR, W.L., ROLLINS, S.A., GUILMETTE, E.R., SETTER, E., and SQUINTO, S.P. (1995). A novel bifunctional chimeric complement inhibitor that regulates C3 convertase and formation of the membrane attack complex. J. Immunol. 155, 4135-4138.
10. GALILI, U., and SWANSON, K. (1991). Gene sequences suggest inactivation of α-1,3-galactosyltransferase in catarrhines after the divergence of apes from monkeys. Proc. Natl. Acad. Sci. U.S.A. 88, 7401-7404.
11. GALELI, U., SHOHET, S.B., KOBRIN, E., STULTS, C.L.M., and MACHER, B.A. (1988). Man, apes, and Old World monkeys differ from other mammals in the expression of α-galactosyl epitopes on nucleated cells. J. Biol. Chem. 263, 17755-17762.
12. HARTMAN, S.C., and MULLIGAN, R.C. (1988). Two dominant-acting selectable markers for gene transfer studies in mammalian cells. Proc. Natl. Acad. Sci. U.S.A. 85, 8047-8051.
13. LI, Y.Y., and PEREZ, L.G. (1997). The entire SU subunit is required for the incorporation of the HIV-1 envelope glycoprotein complex into virions. Virus Genes 14, 211-223.
14. LUBLIN, D.M., and COYNE, K.E. (1991). Phospholipid-anchored and transmembrane versions of either decay-accelerating factor or membrane cofactor protein show equal efficiency in protection from complement-mediated cell damage. J. Exp. Med. 174, 35-44.
15. MIYAO, Y., IKENAKA, K., KISHIMA, H., TAMURA, M., NAKAMURA, K., KURUMI, M., HAYAKAWA, T., and SHIMIZU, K. (1997). FUT-175, a synthetic inhibitor of the complement pathway, protects against the inactivation of infectious retroviruses by human serum. Hum. Gene Ther. 8, 1575-1583.
16. MORGAN, B.P., and MERI, S. (1994). Membrane proteins that protect against complement lysis. Springer Semin. Immunopathol. 15, 369-396.
17. OLDFIELD, E.H., RAM, Z., CULVER, K.W., BLAESE, R.M., DE VROOM, H.L., and ANDERSON, W.F. (1993). Gene therapy for the treatment of brain tumors using intra-tumoral transduction with the thymidine kinase gene and intravenous ganciclovir. Hum. Gene Ther. 4, 39-69.
18. PENSIERO, M.N., WYSOCKI, C.A., NADER, K., and KIKUCHI, G.E. (1996). Development of amphotropic murine retrovirus vectors resistant to inactivation by human serum. Hum. Gene Ther. 7, 1095-1101.
19. POST, T.W., LISZEWSKI, M.K., ADAMS, E.M., TEDJA, I., MILLER, E.A., and ATKINSON, J.P. (1991). Membrane cofactor protein of the complement system: Alternative splicing of serine/threonine/proline-rich exons and cytoplasmic tails produces multiple isoforms that correlate with protein phenotype. J. Exp. Med. 174, 93-102.
20. RAM, Z., WALBRIDGE, S., OSHORO, E.M., VIOLA, J.J., CHIANG, Y., MUELLER, S.N., BLAESE, R.M., and OLDFIELD, E.H. (1994). In situ retroviral-mediated gene transfer for the treatment of brain tumors in rats. Cancer Res. 54, 2141-2145.
21. RIGG, R.J., CHEN, J., DANDO, J.S., FORESTELL, S.P., PLAVEC, I., and BÖHNLEIN, E. (1996). A novel human amphotropic packaging cell line: High titer, complement resistance and improved safety. Virology 218, 290-295.
22. ROLLINS, S.A., BIRKS, C.W., SQUINTO, S.P., and ROTHER, R.P. (1996). Retroviral vector producer cell killing in human serum is mediated by natural antibody and complement: Strategies for evading the humoral immune response. Hum. Gene Ther. 7, 619-626.
23. ROTHER, R.P., and SQUINTO, S.P. (1996). The α-galactosyl epitope: A sugar coating that makes viruses and cells unpalatable. Cell 86, 185-188.
24. ROTHER, R.P., FODOR, W.L., SPRINGHORN, J.P., BIRKS, W.B., SETTER, E., SANDRIN, M.S., SQUINTO, S.P., and ROLLINS, S.A. (1995a). A novel mechanism of retrovirus inactivation in human serum mediated by anti-α-galactosyl natural antibody. J. Exp. Med. 182, 1345-1355.
25. ROTHER, R.P., SQUINTO, S.P., MASON, I.M., and ROLLINS, S.A. (1995b). Protection of retroviral particles in human blood through complement inhibition. Hum. Gene Ther. 6, 429-435.
26. RUSSEL, D.W., BERGER, M.S., and MILLER, A.D. (1995). The effects of human serum and cerebrospinal fluid on retroviral vectors and packaging cell lines. Hum. Gene Ther. 6, 635-641.
27. SAIFUDDIN, M., HEDAYATI, T., ATKINSON, J.P., HOLGUIN, M.H., PARKER, C.J., and SPEAR, G.T. (1997). Human immunodeficiency virus type 1 incorporates both glycosyl phosphatidylinositol-anchored CD55 and CD59 and integral membrane CD46 at levels that protect from complement-mediated destruction. J. Gen. Virol. 78, 1907-1911.
28. SANDRIN, M.S., and McKENZIE, I.F.C. (1994). Gala(1,3)Gal, the major xenoantigen(s) recognized in pigs by human natural antibodies. Immunol. Rev. 141, 169-190.
29. SHIMIZU, K., MIYAO, Y., TAMURA, M., KISHIMA, H., OHKAWA, M., MABUCHI, E., YAMADA, M., HAYAKAWA, T., and IKENAKA, K. (1995). Infectious retrovirus is inactivated by serum but not by cerebrospinal fluid or fluid from tumor bed in patients with malignant glioma. Jpn. J. Cancer Res. 86, 1010-1013.
30. TAKAMIYA, Y., SHORT, M.P., EZZEDINE, Z.D., MOOLTEN, F.L., BREAKFIELD, X.O., and MARTUZA, R.L. (1992). Gene therapy of malignant brain tumors: A rat glioma line bearing the herpes simplex virus type 1-thymidine kinase gene and wild type retrovirus kills other tumor cells. J. Neurosci. Res. 33, 493-503.
31. TAKEUCHI, Y., COSSET, F.L., LACHMANN, P.L., OKADA, H., WEISS, R.A., and COLLINS, M.K. (1994). Type C retrovirus inactivation by human complement is determined by both the viral genome and the producer cell. J. Virol. 68, 8001-8007.
32. TAKEUCHI, Y., PORTER, C.D., STRAHAN, K.M., PREECE, A.F., GUSTAFSSON, K., COSSET, F.L., WEISS, R.A., and COLLINS, M.K. (1996). Sensitization of cells and retroviruses to human serum by (α1-3) galactosyltransferase. Nature (London) 379, 85-89.
33. UDENFRIEND, S., and KODUKULA, K. (1995). How glycosylphosphatidylinositol-anchored proteins are made. Annu. Rev. Biochem. 64, 563-591.
34. WELSH, R.M., COOPER, N.R., IENSEN, F.C., and OLDSTONE, M.B.A. (1975). Human serum lyses RNA tumor viruses. Nature (London) 257, 612-614.
35. WELSH, R.M., COOPER, N.R., JENSEN, F.C., and OLDSTONE, M.B.A. (1976). Inactivation and lysis of oncornaviruses by human serum. Virology 74, 432-440.
36. WIRTH, M., GRANNEMANN, R., KLEHR, D., and HAUSER, H. (1994). Screening retroviral packaging cells for highly efficient virus production by using a combined selection procedure. J. Virol. 68, 566-569.